Lung response to diabetes treatment using GLP-1 receptor agonists in adults with cystic fibrosis: factors linked to better lung function

Obesity and cardiometabolic dysfunction are increasingly recognized in people with cystic fibrosis (pwCF).

• Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may influence lung function and respiratory outcomes in pwCF.
• The relationship between pulmonary improvement and metabolic response after starting GLP-1 RAs is not fully understood.
• Treatment intensity could be a factor in the pulmonary response to GLP-1 RAs in pwCF.

Simplified